Sign in
Taking peoplePhase 4

Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial

Key facts

Who runs it
Pouya Azar
Where
Canada2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
12 people, planned
Started
29 Apr 2026
Planned end
30 Sept 2026
Type of study
Interventional
Treatments tested
  • Naloxone Hydrochloride 0.4 MG/ML
  • Buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablet (2 mg/0.5 mg and 8 mg/2 mg)
  • Buprenorphine extended-release injection (300 mg/1.5 mL)
Record updated
1 May 2026

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • To be eligible for this study, participants must fulfill all the following inclusion criteria:
  • 19 years of age or older
  • Opioid use disorder as confirmed by DSM 5 diagnostic criteria
  • Clinical indication to start OAT with buprenorphine
  • Willingness to tolerate mild opioid withdrawal precipitated by naloxone, expected to last less than 20 minutes
  • Willing and able to have and maintain IV access for the duration of the SINI
  • If of childbearing potential and elected BUP-XR, agree to use an effective method of birth control; o Highly effective methods of birth control include hormonal contraceptives (e.g., combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy and tubal ligation. Effective methods include barrier methods of contraception (e.g., male condom, female condom, cervical cap, diaphragm, contraceptive sponge)
  • Willing and able to provide written informed consent for study participation

Who cannot take part

  • Previous participation in this study (previous receipt of SINI in a clinical setting is not exclusionary)
  • Diagnosis of severe medical or psychiatric conditions contraindicated for naloxone or buprenorphine
  • Known allergy or sensitivity to naloxone or buprenorphine
  • Concomitant use of medications with drug-drug interactions with buprenorphine, unless alternative treatment options are less appropriate and a risk-benefit assessment has been discussed and recommended by the participant's healthcare team; o Examples include, but are not limited to: benzodiazepines and non-benzodiazepine central nervous system depressants, naltrexone, CYP3A4 inhibitors and inducers, serotonergic drugs, monoamine oxidase inhibitors, QTc interval-prolonging drugs, diuretics, anticholinergics, and antiretrovirals
  • If participants meet any of the following exclusion criteria, they will be excluded from participation in the study:
  • Use of BUP/NLX within the past 9 days
  • Use of BUP-XR within the past 43 weeks
  • Currently pregnant or breastfeeding
  • COWS ≥ 8

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical study is to evaluate a new treatment approach called symptom inhibited naloxone induction (SINI) for people with opioid use disorder. In this study, participants will receive small doses of intravenous (IV) naloxone at intervals until they feel mild opioid withdrawal symptoms. At this point, they will be given buprenorphine/naloxone under the tongue to help with the withdrawal symptoms. One hour after, they will receive a injection of long acting buprenorphine under the skin if they choose to.

Read full original descriptionShow less

The main questions this study aims to answer are:

Is it feasible to use the SINI protocol in inpatient and outpatient settings? Is the SINI protocol safe and tolerable for individuals with opioid use disorder?

The group in the trial

  • InterventionTreatment being tested

    Symptom inhibited naloxone induction followed by sublingual buprenorphine/naloxone (2/0.5 mg or 8/2 mg) and extended release buprenorphine injection (300mg/1.5mL)

    Treatment: Naloxone Hydrochloride 0.4 MG/ML, Buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablet (2 mg/0.5 mg and 8 mg/2 mg), and Buprenorphine extended-release injection (300 mg/1.5 mL)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Symptom-inhibited Naloxone Induction (SINI) to Initiate Buprenorphine/Naloxone and Buprenorphine Extended-release for Opioid Use Disorder: A Single-arm Feasibility Trial
Record updated
1 May 2026